Efficacy of Ginseng for Patients on Regorafenib

Summary

This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.

Timeline

Start

2016-04

Primary completion

2018-06-22

Completion

2018-06-22

Outcome

Outcome not reported

Stopped (Business): “Funder terminated.”

Drugs

Indications